Free Pharma Reference
ICH Guidelines Reference
The International Council for Harmonisation (ICH) develops global technical guidelines for pharmaceutical registration. ICH guidelines are adopted by FDA (US), EMA (EU), PMDA (Japan), and most major regulators worldwide — searchable Q/E/S/M index for RA, QA, and clinical teams.
Quick Answer
ICH (International Council for Harmonisation) develops globally adopted pharmaceutical guidelines organized into Q (Quality), E (Efficacy), S (Safety), and M (Multidisciplinary) series. FDA, EMA, and PMDA adopt ICH guidelines as regulatory requirements for drug registration. Key references include Q1A stability, Q8 QbD, Q9 risk management, E6 GCP, E9 statistics, S2 genotoxicity, and M4 CTD/eCTD structure.
ICH Series Overview
Q
Quality Series
Manufacturing, analytical procedures, stability testing, pharmaceutical development (QbD), and quality risk management.
E
Efficacy Series
Clinical trials design, GCP, statistics, pharmacovigilance, and clinical safety data management.
S
Safety Series
Nonclinical safety: toxicology, genotoxicity, carcinogenicity, reproductive toxicity, and safety pharmacology.
M
Multidisciplinary Series
Cross-cutting topics: CTD, eCTD, MedDRA, bioequivalence, drug interactions, and electronic regulatory submissions.
Search All ICH Guidelines
Q Series — Quality Guidelines
| Guideline | Title | Key Scope |
|---|---|---|
| Q1A(R2) | Stability Testing of New Drug Substances and Products | ICH stability conditions, timepoints, storage zones, accelerated and long-term studies |
| Q1B | Photostability Testing of New Drug Substances and Products | Light exposure testing protocol for photostability characterisation |
| Q1C | Stability Testing for New Dosage Forms | Extensions of Q1A to new dosage forms of existing approved drugs |
| Q1D | Bracketing and Matrixing Designs for Stability Testing | Reduced stability study designs — statistical basis and regulatory acceptability |
| Q1E | Evaluation for Stability Data | Statistical analysis and shelf-life estimation from stability data |
| Q1F | Climatic Zones | Withdrawn — replaced by Q1A(R2) provisions for zones III and IV |
| Q2(R1) | Validation of Analytical Procedures: Text and Methodology | Accuracy, precision, linearity, range, LOD, LOQ, specificity, robustness |
| Q3A(R2) | Impurities in New Drug Substances | Reporting, identification, and qualification thresholds for drug substance impurities |
| Q3B(R2) | Impurities in New Drug Products | Degradation products in finished products — thresholds and qualification |
| Q3C(R8) | Impurities: Guideline for Residual Solvents | Class 1, 2, and 3 solvent PDE limits and control strategy |
| Q3D(R2) | Guideline for Elemental Impurities | PDE limits for 24 elements; risk-based control strategy for elemental impurities |
| Q4B | Regulatory Acceptance of Pharmacopoeial Procedures and Acceptance Criteria | Harmonized test methods from USP, Ph. Eur., and JP for mutual acceptance |
| Q5A–Q5E | Quality of Biotechnological Products | Viral safety (Q5A), genetic stability (Q5B), characterization (Q5C), comparability (Q5E) |
| Q6A | Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and Products | Setting release and shelf-life specifications for chemical drug substances and products |
| Q6B | Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products | Biological characterization and specification setting for biotech products |
| Q7 | Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients | GMP requirements for API manufacture — the ICH API GMP guideline |
| Q8(R2) | Pharmaceutical Development | Quality by Design (QbD), design space, control strategy, enhanced product understanding |
| Q9(R1) | Quality Risk Management | FMEA, HACCP, Ishikawa, fault tree analysis — risk management tools for pharmaceutical quality |
| Q10 | Pharmaceutical Quality System | PQS framework — management responsibilities, knowledge management, lifecycle approach |
| Q11 | Development and Manufacture of Drug Substances (Chemical and Biotechnological/Biological Entities) | DS manufacturing guidance — control strategy, development approach, submission expectations |
| Q12 | Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management | Post-approval change management; Established Conditions (ECs), PACMPs, regulatory flexibility |
| Q13 | Continuous Manufacturing of Drug Substances and Drug Products | CM principles, control strategy for continuous processes, regulatory approach for submissions |
| Q14 | Analytical Procedure Development | QbD approach for analytical procedure development; ATP, method operable design region |
E Series — Efficacy Guidelines
| Guideline | Title | Key Scope |
|---|---|---|
| E1 | The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment | Minimum patient exposure requirements for chronic-use drug approvals |
| E2A | Clinical Safety Data Management: Definitions and Standards for Expedited Reporting | SAE, SUSAR definitions; 7-day and 15-day expedited reporting requirements |
| E2B(R3) | Electronic Transmission of Individual Case Safety Reports | XML data format and ICH ICSR data elements for electronic safety report transmission |
| E2C(R2) | Periodic Benefit-Risk Evaluation Report (PBRER) | PBRER content, format, and data lock point — replaces PSUR in ICH regions |
| E2D | Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting | Post-marketing expedited safety reporting standards and definitions |
| E2E | Pharmacovigilance Planning | Safety specification, pharmacovigilance plan, risk management for new products |
| E3 | Structure and Content of Clinical Study Reports | CSR format and content requirements — ICH-standardized clinical study reporting |
| E4 | Dose-Response Information to Support Drug Registration | Dose-response study design — importance of dose-finding for registration dossiers |
| E5(R1) | Ethnic Factors in the Acceptability of Foreign Clinical Data | Bridging studies to extrapolate foreign clinical data to a new region |
| E6(R2) | Good Clinical Practice | GCP standards for design, conduct, monitoring, auditing, recording, and reporting of clinical trials |
| E7 | Studies in Support of Special Populations: Geriatrics | Elderly inclusion requirements and geriatric assessment in drug development |
| E8(R1) | General Considerations for Clinical Studies | Risk-based, fit-for-purpose clinical study design; quality tolerance limits |
| E9(R1) | Statistical Principles for Clinical Trials (Addendum: Estimands) | Estimands framework — intercurrent events, estimand attributes, sensitivity analyses |
| E10 | Choice of Control Group and Related Issues in Clinical Trials | Active vs. placebo controlled trial design; ethical and scientific justification for control group selection |
| E11(R1) | Clinical Investigation of Medicinal Products in the Pediatric Population | Pediatric clinical development requirements, age groupings, and study considerations |
| E14 | The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs | Thorough QT (TQT) studies and concentration-QTc analysis for cardiac safety assessment |
| E17 | General Principles for Planning and Design of Multi-Regional Clinical Trials | MRCT design and analysis — consistency evaluation across regions and subpopulations |
| E19 | Optimisation of Safety Data Collection | Selective approach to safety data collection in Phase III and post-approval studies |
S Series — Safety Guidelines
| Guideline | Title | Key Scope |
|---|---|---|
| S1A | Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals | When carcinogenicity studies are required based on duration of use and patient population |
| S1B | Testing for Carcinogenicity of Pharmaceuticals | Study types for carcinogenicity assessment; 2-year rat study and alternatives |
| S1C(R2) | Dose Selection for Carcinogenicity Studies of Pharmaceuticals | Dose selection rationale for carcinogenicity studies; exposure multiples |
| S2(R1) | Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use | Standard and follow-up genotoxicity battery; in vitro and in vivo study requirements |
| S3A | Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies | Toxicokinetic assessment integrated into repeat-dose toxicity studies |
| S3B | Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies | When tissue distribution studies are required; study design principles |
| S4 | Duration of Chronic Toxicity Testing in Animals | Duration requirements for chronic rodent and non-rodent toxicity studies |
| S5(R3) | Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals | DART studies: fertility, embryo-fetal development, pre/postnatal development study requirements |
| S6(R1) | Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals | Nonclinical safety for biologics; species selection, immunogenicity, relevant animal models |
| S7A | Safety Pharmacology Studies for Human Pharmaceuticals | Core battery (CNS, CV, respiratory) and follow-up safety pharmacology requirements |
| S7B | The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization by Human Pharmaceuticals | hERG assay and in vivo cardiac safety pharmacology for QT prolongation risk |
| S8 | Immunotoxicity Studies for Human Pharmaceuticals | Weight-of-evidence approach for immunotoxicity; when dedicated studies are needed |
| S9 | Nonclinical Evaluation for Anticancer Pharmaceuticals | Tailored nonclinical requirements for oncology drugs; timing relative to clinical trials |
| S10 | Photosafety Evaluation of Pharmaceuticals | In vitro and in vivo photosafety studies; phototoxicity and photocarcinogenicity assessment |
| S11 | Nonclinical Safety Testing in Support of Development of Paediatric Medicines | Juvenile animal studies — when required, species selection, endpoints for paediatric development |
| S12 | Nonclinical Biodistribution Considerations for Gene Therapy Products | Biodistribution studies for gene therapy vectors; sampling strategy and study design |
M Series — Multidisciplinary Guidelines
| Guideline | Title | Key Scope |
|---|---|---|
| M1 | MedDRA — Medical Dictionary for Regulatory Activities | Standardized medical terminology for adverse events, diagnoses, and medical history coding in regulatory submissions |
| M2 | Electronic Standards for the Transfer of Regulatory Information (ESTRI) | Electronic standards for regulatory information exchange between industry and health authorities |
| M3(R2) | Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals | Timing of nonclinical toxicology studies relative to clinical trial phases and marketing authorization |
| M4 | Common Technical Document (CTD) | Five-module CTD structure for global regulatory submissions; harmonized format for NDA/BLA/MAA/J-NDA |
| M5 | Data Elements and Standards for Drug Dictionaries | Drug dictionary standards for exchange of product information between regulatory stakeholders |
| M7(R2) | Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk | TTC (threshold of toxicological concern) approach; acceptable intakes for genotoxic impurities |
| M8 | Electronic Common Technical Document (eCTD) | Technical specification for eCTD submissions; required by FDA, EMA, PMDA, and most major agencies |
| M9 | Biopharmaceutics Classification System-Based Biowaivers | BCS Class I and III biowaivers for oral solid dosage forms; in vitro dissolution as surrogate for BE |
| M10 | Bioanalytical Method Validation and Study Sample Analysis | Validation requirements for bioanalytical methods used to measure drug concentrations in PK samples |
| M11 | Clinical Electronic Structured Harmonised Protocol (CeSHarP) | Structured electronic protocol format for clinical trials — harmonized data model for protocol content |
| M12 | Drug Interaction Studies | In vitro and in vivo DDI studies; enzyme/transporter evaluation, labeling implications |
| M13A | Bioequivalence for Immediate Release Solid Oral Dosage Forms | BE study design, statistical requirements, and acceptance criteria for IR solid oral forms |
Pharma & Regulatory Affairs Context
ICH guidelines form the backbone of global drug registration dossiers. RA teams reference M4/M8 for eCTD structure, Q1A for stability protocols, Q3A/Q3B for impurity thresholds, E6 for GCP compliance, and E2A–E2E for pharmacovigilance reporting. QA teams rely on Q7 (API GMP), Q9 (risk management), and Q10 (PQS) for quality system design.
Cross-link to Pharma Acronyms for abbreviation lookups, FDA Submission Types for pathway context, eCTD Structure Guide for module publishing, and Process Capability Cpk for Q8/Q9 manufacturing quality tools.
Evidence & Sources
- ICH.org — Q Series Quality Guidelines
- ICH.org — E Series Efficacy Guidelines
- EMA ICH Guidelines Hub — EU adoption status
- FDA Guidance Documents — Q Quality series
Competitive landscape: ICH.org provides official guideline PDFs but no searchable cross-series index with scope summaries. EMA's ICH hub covers EU adoption status but requires navigation across multiple pages without integrated Q/E/S/M search. FDA's Q-series pages are single-series references without E/S/M coverage in one view. NovaPharmaNews combines tabbed Q/E/S/M tables, live search, scope summaries, and regulatory cluster links — free, no login.
Frequently Asked Questions
ICH guidelines become mandatory when formally adopted by regional regulators. FDA adopts ICH guidelines as guidance documents and references them in regulations. EMA publishes adopted ICH guidelines as CHMP guidelines. PMDA incorporates ICH guidelines into Japanese regulations. Most ICH guidelines are adopted and treated as regulatory requirements in practice by FDA, EMA, and PMDA.
Q10 (Pharmaceutical Quality System) is foundational — it establishes the PQS framework governing pharmaceutical development and manufacturing throughout the product lifecycle. Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), and Q10 together form the pharmaceutical development triad and are collectively considered the cornerstone of the modern QbD-based approach.
E6(R2) covers Good Clinical Practice. It sets international quality standards for designing, conducting, recording, and reporting clinical trials. The R3 revision is under development and will introduce a more risk-based, proportionate approach to GCP oversight. E6(R2) is adopted by FDA, EMA, PMDA, Health Canada, and most major global regulators.
Q1A(R2) covers primary stability testing conditions, timepoints, and acceptance criteria for new drug substances and products. Q1B covers photostability testing. Q1D covers bracketing and matrixing designs for reduced stability testing. Q1E covers statistical evaluation and shelf-life estimation from stability data.
ICH stands for the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Founded in 1990 as the International Conference on Harmonisation and renamed in 2015, ICH brings together regulatory authorities and the pharmaceutical industry to develop globally harmonized guidelines for drug approval.
ICH Q8(R2) defines Pharmaceutical Development using Quality by Design principles — predefined objectives, design space, control strategy, and enhanced product and process understanding. QbD is the scientific foundation for modern drug development and is referenced in FDA and EMA quality guidelines for both chemical and biotechnological products.
ICH Q9(R1) provides principles and tools for quality risk management in pharmaceutical development and manufacturing. It covers FMEA, HACCP, fault tree analysis, and risk ranking. Q9 is foundational for CAPA prioritization, change control, and validation decisions in GMP environments.
ICH M4 defines the five-module CTD structure for global regulatory submissions: Module 1 (regional administrative), Module 2 (summaries), Module 3 (Quality/CMC), Module 4 (Nonclinical), and Module 5 (Clinical). M8 specifies the electronic eCTD format required by FDA, EMA, and PMDA.
E6(R2) covers Good Clinical Practice — standards for trial conduct, monitoring, auditing, and reporting. E8(R1) covers General Considerations for Clinical Studies — risk-based, fit-for-purpose study design with quality tolerance limits. E6 governs how trials are executed; E8 governs how they are designed.
ICH S2(R1) provides guidance on genotoxicity testing and data interpretation for pharmaceuticals. It defines the standard battery (in vitro bacterial mutation assay plus in vitro mammalian cell assay, with in vivo follow-up as needed) and follow-up study strategies when initial results are positive or equivocal.
ICH Q3D(R2) sets permitted daily exposure (PDE) limits for 24 elemental impurities in drug products based on toxicological data and route of administration. It requires a risk-based control strategy using ICH Q9 principles, with testing or justification based on elemental source assessment.
ICH M7(R2) addresses assessment and control of DNA-reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. It uses the Threshold of Toxicological Concern (TTC) approach and defines acceptable intakes for genotoxic impurities in drug substances and products based on cumulative exposure.